Summary

for people ages 2-21 (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

This is an observational, multicenter study to determine the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were seen at each study site prior to that site's initiation, or by entering care at the site while the site is participating in the trial.

Official Title

An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed With Early-Onset Idiopathic Bilateral Cataracts

Keywords

Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosisCTX Prevalence StudyCTXIdiopathic Bilateral CataractsCataractsBilateral CataractsEarly-Onset Idiopathic Bilateral CataractsObservational StudyOphthalmologyCataractXanthomatosisXanthomatosis, Cerebrotendinous

Eligibility

You can join if…

Open to people ages 2-21

  1. The patient has a diagnosis of idiopathic bilateral cataracts.
  2. Between the ages of 2 to 21 years at the time of diagnosis

You CAN'T join if...

  1. The patient has a diagnosis of cataracts with known etiology other than CTX.
  2. The patient has a diagnosis of CTX.
  3. The patient has cataracts caused by cataractogenic treatments.
  4. The patient has taken or is currently taking cholic acid or chenodeoxycholic acid.
  5. The patient has participated in an interventional clinical trial in the past 30 days.
  6. The patient and/or their parent/legal guardian, in the opinion of the Investigator, is unable to adhere to the requirements of the study.

Locations

  • University of California, San Diego accepting new patients
    La JollaCalifornia92093United States
  • Children's Hospital of Los Angeles accepting new patients
    Los AngelesCalifornia90027United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Retrophin, Inc.
ID
NCT02638220
Study Type
Observational
Last Updated